MOISÉS
GARCÍA ARENCIBIA

Investigador contratado

Foto de MOISÉS

Foto de Hospital Universitario Reina Sofia

Hospital Universitario Reina Sofia

Córdoba, España

Publikationen in Zusammenarbeit mit Forschern von Hospital Universitario Reina Sofia (4)

2018

Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson's disease: Possible involvement of different binding sites at the PPARγ receptor
Journal of Neuroinflammation, Vol. 15, Núm. 1

2017

Corrigendum to “Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile” [Pharmacol. Res. (2016) 110(2016) (205–215)] (S1043661816302080) (10.1016/j.phrs.2016.03.021)
Pharmacological Research

2016

Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile
Pharmacological Research, Vol. 110, pp. 205-215
Tricyclic pyrazoles. Part 8. Synthesis, biological evaluation and modelling of tricyclic pyrazole carboxamides as potential CB2receptor ligands with antagonist/inverse agonist properties
European Journal of Medicinal Chemistry, Vol. 112, pp. 66-80